Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DARPA Device Cleans Wounded Soldiers' Blood (Also, see the comments at the bottom of the article)
http://www.designnews.com/document.asp?doc_id=244118&dfpPParams=ind%5F184%2Cindustry%5Fgov%2Cindustry%5Fmedical%2Caid%5F244118&dfpLayout=article&piddl_msgpage=1#msgs
Ultrasensitive biosensor promising for medical diagnostics (Can sepsis be a possible application also?)
http://investorshub.advfn.com/boards/post_new.aspx?board_id=3094
Effect of hepatitis C virus and its treatment on survival†‡
Adeel A. Butt1,2,3,§,*, Xiaoqiang Wang2, Charity G. Moore1
Conclusion: HCV infection is associated with a substantial increase in mortality. Subjects who are initiated on treatment, and particularly those who proceed to finish a full course of treatment, have significantly reduced risk of mortality. Further studies are warranted to determine the effect of virological control on survival. (HEPATOLOGY 2009.)
CDC Invites Public Comment on Draft Recommendations for One-Time Hepatitis C Testing for Baby Boomers
http://blog.aids.gov/2012/05/cdc-invites-public-comment-on-draft-recommendations-for-one-time-hepatitis-c-testing-for-baby-boomers.html?utm_source=feedburner&utm_medium=email&utm_campaign=Feed%3A+aids%2Fgov+%28Blog.AIDS.gov%29&utm_content=Yahoo%21+Mail
DaVita looks to new healthcare model with $4.42 billion deal
http://finance.yahoo.com/news/davita-buy-healthcare-partners-4-104534036.html
DARPA Funding for Innovative ‘Blood Cleaning’ Device
http://globalbiodefense.com/2012/05/16/darpa-funding-for-innovative-‘blood-cleaning’-device/
Aethlon Medical to Present at Today's Security Research Associates 8th Annual Growth Conference
http://aethlonmedical.investorroom.com/index.php?s=19
The high comorbidity burden of the hepatitis C virus infected population in the United States
Karly S Louie1*, Samantha St Laurent2, Ulla M Forssen3, Linda M Mundy3 and Jeanne M Pimenta1
Abstract
Background
Chronic hepatitis C (HCV) disease can be complicated with comorbid conditions that may impact treatment eligibility and outcomes. The aim of the study was to systematically review comorbidities and symptoms in an HCV infected population, specifically assessing comorbidities associated with HCV anti-viral treatment and disease, as well as comparing comorbidities between an HCV infected and uninfected control population.
Methods
This was a retrospective cohort study within a United States medical claims database among patients with chronic HCV designed to estimate the two-year period prevalence of comorbidities. Patients with two HCV diagnosis codes, 24 months of continuous health insurance coverage, and full medical and pharmacy benefits were included.
Results
Among a chronic HCV cohort of 7411 patients, at least one comorbid condition was seen in almost all patients (> 99%) during the study period. HCV-infected patients reported almost double the number of comorbidities compared to uninfected controls. Of the 25 most common comorbidities, the majority of the comorbidities (n = 22) were known to be associated with either HCV antiviral treatment or disease. The five most frequent comorbidities were liver disease [other] (37.5%), connective tissue disease (37.5%), abdominal pain (36.1%), upper respiratory infections (35.6%), and lower respiratory disease (33.7%). Three notable comorbidities not known to be associated with antiviral treatment or disease were benign neoplasms (24.3%), genitourinary symptoms & ill-defined conditions (14.8%), and viral infections (13.8%).
Conclusions
This US medically insured HCV population is highly comorbid. Effective strategies to manage these comorbidities are necessary to allow wider access to HCV treatment and reduce the future burden of HCV disease and its manifestations.
© 2012 Louie et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
bigfish1972
Welcome.
I have been following AEMD for a long time. The broad spectrum capabilities of the HP are well known to long term followers of this stock. However all these years we had something similar to small or individual case studies of the HP with different applications. Now finally, we are seeing results (albeit partial) of what the medical community/FDA likes to see - a clinical trial. The results are better then what I had expected. This PR is loaded with some strong info. e.g. 3 patients have an undetectable viral load after 48 weeks! If this is going to be reflective of the future with more patients, then it would be interesting to see what steps JJ takes. I say this because if this were the results of a drug trial the valuation of AEMD would be in hundreds of millions already if not billions. I may be wrong but I do not think that there has been a drug in the HCV field which has given such results. If the HP was a drug, AEMD would have been an attractive partnership/takeover candidate for major pharmas. But the HP concept is new in medicine and that may make the medical community a bit wary and suspicious. Also, I think the fact that usually HCV is treated by Gastroenterologists and not kidney doctors, is the biggest obstacle to the HP. The renal doctors may embrace it without problems but to get patients for treatments they still need referals from other MDs like primary care doctors. So, this may involve education of a lot of the medical community which can be a daunting task for a small setup like AEMD.
I think there are 2 answers to this - either the Govt. or a big dialysis company or even better both!
With the current trends to curtail healthcare costs, which is being encouraged by the govt. and insurance companies, the HP should be a no brainer. The main step would be to expose it to the correct people. A better and more financially sound option would be if a major dialysis co. sees the potential of the HP and teams up with AEMD. With their already existing infrastructure and financial backing AEMD would reap rewards immediately.
In the next few months we should hear a lot more from AEMD about the HP with regards to HCV and Sepsis.
ibox updated.
Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy
http://finance.yahoo.com/news/aethlon-medical-reports-undetectable-hepatitis-133000877.html
Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
http://aethlonmedical.investorroom.com/index.php?s=43
My inderstanding is that it is under a hundred and twelve million.
From the DARPA program managers slide -
Platform device could revolutionize multiple areas of medicine:
Sepsis
Wound Infection
CBRN Defense
Trauma
Regenerative Medicine
Autoimmune
Cancer
Diabetes
Cardiovascular
This is what Darpa's vision for DLT is!! The foresight they have is amazing. And they are bringing together very thoughtfully the best minds in the country in different fields. This is something which I think would be very difficult for a big pharma to do.
Also, with my limited knowledge, so far it seems like AEMD is the best bet for multiple applications. What surprises me is that they have not mentioned HIV/HCV which are both significant reasons for chronic sickness like diabetes, autoimmune disease etc.,
The high comorbidity burden of the hepatitis C virus infected population in the United States
Karly S Louie, Samantha St. Laurent, Ulla M Forssen, Linda M Mundy and Jeanne M Pimenta
BMC Infectious Diseases 2012, 12:86 doi:10.1186/1471-2334-12-86
Published: 11 April 2012
Abstract (provisional)
Background
Chronic hepatitis C (HCV) disease can be complicated with comorbid conditions that may impact treatment eligibility and outcomes. The aim of the study was to systematically review comorbidities and symptoms in an HCV infected population, specifically assessing comorbidities associated with HCV anti-viral treatment and disease, as well as comparing comorbidities between an HCV infected and uninfected control population.
Methods
This was a retrospective cohort study within a United States medical claims database among patients with chronic HCV designed to estimate the two-year period prevalence of comorbidities. Patients with two HCV diagnosis codes, 24 months of continuous health insurance coverage, and full medical and pharmacy benefits were included.
Results
Among a chronic HCV cohort of 7411 patients, at least one comorbid condition was seen in almost all patients (>99%) during the study period. HCV-infected patients reported almost double the number of comorbidities compared to uninfected controls. Of the 25 most common comorbidities, the majority of the comorbidities (n = 22) were known to be associated with either HCV antiviral treatment or disease. The five most frequent comorbidities were liver disease [other] (37.5%), connective tissue disease (37.5%), abdominal pain (36.1%), upper respiratory infections (35.6%), and lower respiratory disease (33.7%). Three notable comorbidities not known to be associated with antiviral treatment or disease were benign neoplasms (24.3%), genitourinary symptoms & ill-defined conditions (14.8%), and viral infections (13.8%).
Conclusions
This US medically insured HCV population is highly comorbid. Effective strategies to manage these comorbidities are necessary to allow wider access to HCV treatment and reduce the future burden of HCV disease and its manifestations.
Predictive Modeling of Patient State and Therapy Optimization
http://www.dabi.temple.edu/dabi/people/zoran/research/darpa_therapy.html
A biomimetic membrane device that modulates the excessive inflammatory response to sepsis.
http://www.ncbi.nlm.nih.gov/pubmed/21533222?dopt=Abstract
Starfruit-Shaped Gold Nanorods and Nanowires: Synthesis and SERS Characterization
http://pubs.acs.org/doi/abs/10.1021/la300218z
Founding Director of Harvard's Wyss Institute Elected to the College of Fellows of the American Institute for Medical and Biological Engineering
http://wyss.harvard.edu/viewpressrelease/51/founding-director-of-harvards-wyss-institute-elected-to-the-college-of-fellows-of-the-american-institute-for-medical-and-biological-engineering
Harvard's Wyss Institute Creates Living Human Gut-on-a-Chip
http://wyss.harvard.edu/viewpressrelease/80/
Microfluidic Chip Demonstrates Rapid, Low Cost, Point-of-Care Flu Detection
http://www.bu.edu/phpbin/news-cms/news/?dept=666&id=59219
Research Assistant IV - Microdevice Design Technician
School/Unit Harvard Medical School
Sub-Unit Wyss Institute
https://sjobs.brassring.com/1033/asp/tg/cim_jobdetail.asp?partnerID=25240&siteID=5341&AReq=25798BR
Staff Engineer - Blood-Compatible Medical Device Engineering (Spleen on a chip!)
School/Unit Harvard Medical School
Sub-Unit Wyss Institute
https://sjobs.brassring.com/1033/asp/tg/cim_jobdetail.asp?partnerID=25240&siteID=5341&AReq=25284BR
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (Strong case for the HP to decrease the viral load and be an adjuvant for universal treatment)
http://www.aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/
From HIV and Hepatitis.com
In early 2010San Francisco General Hospital (SFGH) and other facilities run by the San Francisco Department of Public Health (SFDPH) adopted a controversial policy of providing ART to all patients diagnosed with HIV, rather than waiting until CD4 counts fell into the 350-500 cells/mm3 range specified in the U.S. DHHS treatment guidelines in effect at the time. Updated guidelines released this week now also recommend universal treatment for everyone diagnosed with HIV.
At CROI, Elvin Geng and colleagues from the University of California at San Francisco (UCSF) presented findings from a study of clinical practice and patient outcomes since the new policy went into effect.
The analysis included untreated adult patients (defined as at least 90 days without ART) who made at least 1 primary care visit to SFGH's Ward 86 HIV/AIDS Clinic between 2000 and 2011.
"In a public health setting with patients with multiple co-morbidities, treatment of patients who enter with CD4 levels > 500 [cells/mm3] is acceptable and feasible," they concluded. "Successful implementation of universal treatment has the potential to benefit the health of the individual and reduce new infections in San Francisco."
Broader Screening for Hepatitis C Would Be Cost Effective, Study Suggests
http://www.idsociety.org/BroaderScreeningforHepatitisC/
Increase of HCV RNA concentration during hemodialysis treatment in patients with chronic hepatitis C
In contrast to recent publications, a significant increase of serum HCV RNA within 180min after start of HD or HDF was observed. Changes in serum HCV RNA concentration are independent from HD and HDF procedures, dialysis membrane, heparin concentration, and uremic toxins.
Journal of Clinical Virology, 03/19/2012 Putz–Bankuti C et al. –
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
CONCLUSIONS
The early initiation of antiretroviral therapy reduced rates of sexual transmission of HIV-1 and clinical events, indicating both personal and public health benefits from such therapy. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 052 ClinicalTrials.gov number, NCT00074581.)
http://www.nejm.org/doi/full/10.1056/NEJMoa1105243
New Stanford immune-system sensor may speed up, slash cost of detecting disease
http://med.stanford.edu/ism/2012/march/waveguide.html
From CROI - very interesting lecture - explains about the HIV surface structure. This makes it simpler to understand why the HP is so effective against HIV
http://app2.capitalreach.com/esp1204/servlet/tc?c=10164&cn=retro&s=20481&&dp=player.jsp&e=16605&mediaType=slideVideo
PDQTail - do not recollect seeing you here before- welcome to the board.
UT Researchers Invent Device to Rapidly Detect Infectious Disease
http://www.utk.edu/tntoday/2012/03/01/researchers-invent-device-detect-disease/
HCAB Position Statement: Hepatitis C Drug Development and Drug-Drug Interaction Studies
http://www.treatmentactiongroup.org/hcv/2012/hepatitis-c-drug-development-and-drug-drug-interaction-studies
DARPA-BAA-11-30_DLT_Final For Posting_8Feb11.docx
http://pdaja.info/Read/_xsd.d3d3LmZiby5nb3Y-_xsd..qj_download.qj_138.qj_13805ddec27fbc0e3a909c98d9a3ea0e.qj_DARPA-BAA-11-30_DLT_Final_For_Posting_8Feb11.pdf.html
Vineet Bhandari is the Co-Investigator on the DARPA (Defense Advanced Research Projects Agency) grant {$1,194, 292 total costs}: Dialysis-Like Therapeutics, 10/1/2011-9/30/2015. Yale PI: Corey O’Hern, PhD.
http://www.yalepediatrics.org/news/index.aspx